Raju  Prasad net worth and biography

Raju Prasad Biography and Net Worth

Raju Prasad, Ph.D., has served as our Chief Financial Officer since March 14, 2023. Prior to joining our company, he served in various roles at William Blair & Company from March 2014 to March 2023, most recently as a Partner since January 2021. While at William Blair, he was a senior biotechnology analyst covering small-cap, mid-cap and large-cap companies. Raj led the firms’ initiative on launching coverage in the areas of cell therapy, gene therapy, and gene editing. He previously worked as a research associate with the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health and as an independent consultant with the U.S. Environmental Protection Agency. He also serves on the advisory board of Portal Innovations, a life sciences venture development engine. Raj has a B.A. in cell biology and neuroscience from Rutgers University, an M.S. in exercise physiology from the University of Delaware, and a Ph.D. in environmental sciences and engineering from the University of North Carolina at Chapel Hill with a focus in genetic toxicology and mutagenesis. He has authored several publications in scientific journals and is the author of Building Breakthroughs: On the Frontier of Medical Innovation.

What is Raju Prasad's net worth?

The estimated net worth of Raju Prasad is at least $310,394.68 as of March 15th, 2024. Dr. Prasad owns 6,476 shares of CRISPR Therapeutics stock worth more than $310,395 as of October 30th. This net worth approximation does not reflect any other assets that Dr. Prasad may own. Learn More about Raju Prasad's net worth.

How do I contact Raju Prasad?

The corporate mailing address for Dr. Prasad and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected]. Learn More on Raju Prasad's contact information.

Has Raju Prasad been buying or selling shares of CRISPR Therapeutics?

Raju Prasad has not been actively trading shares of CRISPR Therapeutics over the course of the past ninety days. Most recently, Raju Prasad sold 3,524 shares of the business's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $72.69, for a transaction totalling $256,159.56. Following the completion of the sale, the chief financial officer now directly owns 6,476 shares of the company's stock, valued at $470,740.44. Learn More on Raju Prasad's trading history.

Who are CRISPR Therapeutics' active insiders?

CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Julianne Bruno (COO), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), Raju Prasad (CFO), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.

Are insiders buying or selling shares of CRISPR Therapeutics?

In the last year, insiders at the sold shares 13 times. They sold a total of 162,740 shares worth more than $10,845,712.47. The most recent insider tranaction occured on October, 14th when General Counsel James R Kasinger sold 1,089 shares worth more than $50,398.92. Insiders at CRISPR Therapeutics own 4.1% of the company. Learn More about insider trades at CRISPR Therapeutics.

Information on this page was last updated on 10/14/2024.

Raju Prasad Insider Trading History at CRISPR Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2024Sell3,524$72.69$256,159.566,476View SEC Filing Icon  
See Full Table

Raju Prasad Buying and Selling Activity at CRISPR Therapeutics

This chart shows Raju Prasad's buying and selling at CRISPR Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CRISPR Therapeutics Company Overview

CRISPR Therapeutics logo
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Read More

Today's Range

Now: $47.93
Low: $47.60
High: $49.87

50 Day Range

MA: $47.18
Low: $44.62
High: $49.99

2 Week Range

Now: $47.93
Low: $39.76
High: $91.10

Volume

1,161,738 shs

Average Volume

1,444,757 shs

Market Capitalization

$4.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68